GENE ONLINE|News &
Opinion
Blog

2022-12-29| In-DepthSpecial

64th ASH Annual Meeting and Exposition: Standard Treatments Face Challenges

by Justine Zhu
Share To
Standard treatments face challenges with new evidence. This time at the 64th ASH meeting, two drugs for blood cancers, Blinatumomab and Zanubrutinib, revealed their latest data from clinical trials in the Selected Latest Breaking Abstract section. It also presents the early results of the first-in-class drug Iptacopan for the rare disease paroxysmal nocturnal hemoglobinuria. One of the speeches in this session gave a good example. Dr. Saskia Middeldorp presented that heparin has no benefit in raising the live birth rate in inherited thrombophilia women with recurrent miscarriages. Previously, heparin injection was a standard treatment for women with recurrent miscarriage inherited thrombophilia, but without randomized controlled studies to prove the effectiveness.

GO Prime with only $1.49 now

LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top